21.08.2024 – 02:00 a.m.

BOSTON–(BUSINESS WIRE)– PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half year results for the six months ended June 30, 2024 on Wednesday, August 28, 2024.

A presentation and conference call for analysts and shareholders will be held at 9:00 a.m. EDT (2:00 p.m. BST) on the day of the announcement. A webcast of the presentation will be available on the Company’s website at https://investors.puretechhealth.com/events-presentations.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company committed to developing new classes of medicines to improve the lives of patients with devastating diseases. The company has built a broad and deep pipeline, driven both internally and through its incubated companies, through its experienced research and development team and extensive network of scientists, clinicians and industry leaders. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapy candidates, including two that have received both regulatory approval and regulatory submission requirements for therapeutic approval. US FDA approval and European marketing authorization and a third (KarXT) has been submitted for FDA approval. A number of these programs are being advanced by PureTech or its incubated companies in various indications and phases of clinical development, including pivotal trials. All of the underlying programs and platforms that led to this pipeline of therapeutic candidates were initially identified or discovered and then advanced through key validation points by the PureTech team.

For more information visit www.puretechhealth.com or contact us via X (formerly Twitter) @puretechh.

Cautionary note regarding forward-looking statements

This press release contains statements that are, or may be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release should be considered forward-looking statements, including, without limitation, those relating to PureTech’s development plans and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance or achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC, and our other regulatory filings. These forward-looking statements are based on assumptions regarding the Company’s current and future business strategies and the environment in which it will operate in the future. Each forward-looking statement speaks only as of the date of this press release. Except as required by law or regulation, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View original version on businesswire.com: https://www.businesswire.com/news/home/20240820540519/en/

PureTech

Public relations

[email protected]

Investor information

[email protected]

United Kingdom/EU media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

[email protected]

US media

Nichole Bobby

+1 774 278 8273

[email protected]

Source: PureTech Health plc